|
JP2009143936A
|
|
Preventive or therapeutic agent for disease accompanied by vascular function anomaly associated with insulin resistance
|
|
CN101808646A
|
|
Agent for improving motor complications or psychiatric symptoms in parkinson's disease
|
|
KR20100040276A
|
|
Method for constructing mass of myocardial cells and use of the myocardial cell mass
|
|
WO2009005140A1
|
|
C-terminal-α-amidated recombinant enzyme derivative
|
|
CA2661078A1
|
|
Lyophilized preparation
|
|
US2010004267A1
|
|
Liquid preparation
|
|
WO2007139230A1
|
|
Seven-membered ring compound, production method thereof and pharmaceutical use thereof
|
|
KR20090009267A
|
|
Method for differentiation induction of myocardial cell from pluripotent stem cell
|
|
WO2007114351A1
|
|
Novel cell culture method and methods of producing and collecting cell masses using the same
|
|
CA2640644A1
|
|
A method for purifying cardiomyocytes or programmed cardiomyocytes derived from stem cells or fetuses
|
|
MX2008008584A
|
|
Anti-periostin antibody and pharmaceutical composition for preventing or treating periostin-related disease containing the same.
|
|
CA2635849A1
|
|
An antibody against periostin, and a pharmaceutical composition comprising it for preventing or treating a disease in which periostin is involved
|
|
WO2007072911A1
|
|
Preparation with improved bioabsorbability of sapropterin hydrochloride
|
|
JP2008137897A
|
|
New imidazolone compound
|
|
CA2630006A1
|
|
Skin repair accelerating therapeutic agent containing ghrelin and derivatives thereof or substance acting on ghs-r1a as active ingredient
|
|
BRPI0610089A2
|
|
insulin resistance enhancer
|
|
SG148197A1
|
|
Method for proliferating cardiomyocytes
|
|
CN1816353A
|
|
Medicinal composition for preventing or treating Th1 type immunological disease
|
|
US2006058521A1
|
|
Processes for preparation of organic compounds
|
|
EP1281759A1
|
|
Method of inhibiting the formation of by-product in the production of genetically modified polypeptide
|
